NCT04706936 2023-02-06
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
Clinical Trials
10 trialsNCT05008536 2021-11-23
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03380039 2020-10-12
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase NA Unknown
NCT03716856 2020-10-08
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
First Affiliated Hospital of Zhejiang University
Phase 1 Unknown
NCT04008888 2019-07-05
a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Unknown
NCT03322735 2017-12-29
Study of BCMA CAR-T in Multiple Myeloma
Henan Cancer Hospital
Phase 1/2 Unknown
NCT02457650 2016-08-03
T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies
Shenzhen Second People's Hospital
Phase 1 Unknown
NCT00382694 2006-09-29
Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients
Nordic Myeloma Study Group
Phase 2 Unknown